These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27251593)

  • 21. Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma.
    Dervisis NG; Dominguez PA; Sarbu L; Newman RG; Cadile CD; Swanson CN; Kitchell BE
    J Am Vet Med Assoc; 2007 Aug; 231(4):563-9. PubMed ID: 17696856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
    Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
    Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs.
    Griessmayr PC; Payne SE; Winter JE; Barber LG; Shofer FS
    J Vet Intern Med; 2009; 23(6):1227-31. PubMed ID: 19709354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
    Parsons-Doherty M; Poirier VJ; Monteith G
    Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of Bleomycin and Cytosine Arabinoside Chemotherapy for Relapsed Canine Lymphoma.
    Batschinski K; Dervisis N; Kitchell B; Newman R; Erfourth T
    J Am Anim Hosp Assoc; 2018; 54(3):150-155. PubMed ID: 29558212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.
    Treggiari E; Elliott JW; Baines SJ; Blackwood L
    Vet Comp Oncol; 2018 Jun; 16(2):194-201. PubMed ID: 28766920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
    Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
    J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of clinical response and prognostic factors in canine multicentric lymphoma treated with first rescue therapy.
    Blaxill JE; Bennett PF
    Vet Comp Oncol; 2024 Jun; 22(2):265-277. PubMed ID: 38646859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
    Tanis JB; Mason SL; Maddox TW; Blackwood L; Killick DR; Amores-Fuster I; Harper A; Finotello R
    Vet Comp Oncol; 2018 Sep; 16(3):361-369. PubMed ID: 29380942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
    Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD
    J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
    Davies O; Szladovits B; Polton G; Garden OA; Leo C; Lara-Garcia A
    Vet Comp Oncol; 2018 Jun; 16(2):276-287. PubMed ID: 29271043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy.
    Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
    J Vet Intern Med; 2011; 25(2):292-6. PubMed ID: 21314721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
    Cooper M; Tsai X; Bennett P
    Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
    Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
    J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma.
    Moore AS; Cotter SM; Rand WM; Wood CA; Williams LE; London CA; Frimberger AE; L'Heureux DA
    J Vet Intern Med; 2001; 15(4):348-54. PubMed ID: 11467592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of canine lymphoma with COPLA/LVP.
    Boyce KL; Kitchell BE
    J Am Anim Hosp Assoc; 2000; 36(5):395-403. PubMed ID: 10997514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
    Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
    J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral melphalan for the treatment of relapsed canine lymphoma.
    Mastromauro ML; Suter SE; Hauck ML; Hess PR
    Vet Comp Oncol; 2018 Mar; 16(1):E123-E129. PubMed ID: 28941072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
    Burton JH; Garrett-Mayer E; Thamm DH
    Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asparaginase and MOPP treatment of dogs with lymphoma.
    Brodsky EM; Maudlin GN; Lachowicz JL; Post GS
    J Vet Intern Med; 2009; 23(3):578-84. PubMed ID: 19645842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.